Royalty Report: Drugs, Disease, Therapeutic – Collection: 203334

$100.00

Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3

Description

This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Disease
  • Therapeutic
  • Vaccine
  • Antibody
  • Respiratory
  • DNA
  • HIV / AIDs

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 203334

License Grant
Licensor grants an exclusive license, including the right to grant sublicenses to third parties, under the Licensor Technology and Joint Patent Rights, to the extent necessary to make, have made, and use the Selected Immune Modulators to develop, make, have made, use, sell, have sold, offer for sale, and import the Products in the Field, including the right to make, have made, use, sell, have sold and import metabolites incidental to the manufacture, storage, and use of Products in the Field, in the Territory, and, an exclusive license, including the right to grant sublicenses to third parties or approved in writing by Licensor, under the Licensor Technology and Joint Patent Rights, to the extent necessary for Licensee to perform in vivo testing during the Option Term,  on the up to twenty-eight (28) Immunomodulatory Oligonucleotides run through Step 2, and an exclusive license, including the right to grant sublicenses to third parties, under the Licensor Technology and Joint Patent Rights to perform research and development on the Licensee Immune Modulators in order to select the Selected Immune Modulators.

In the event Licensee determines that it would like to grant a sublicense in a Major Market Country with respect to any of the rights granted by Licensor, Licensor shall have a right of first negotiation to obtain such sublicense.

Licensees right to grant sublicenses in any country other than a Major Market Country with respect to any of the rights granted by Licensor hereunder shall be subject to Licensor’s prior written consent.

License Property
The technology and patents relate to Immune Modulators.  The Product shall mean a drug product consisting of at least one Selected Immune Modulator formulated as a monotherapy or a Combination Product.  Immune Modulators shall mean CpG 7909, CpG 7279 and the Licensee Immune Modulators.
Field of Use
Field shall mean the use of Immune Modulators solely for prophylactic and/or therapeutic treatment of asthma, allergic rhinitis or COPD, administered via a Delivery Method. The Field specifically excludes, without limitation the use of Immune Modulators for all other allergic indications, atopic indications, autoimmune disorders and/or inflammatory disorders; and/or any administration of Immune Modulators other than via a Delivery Method; and/or any and all drug combinations incorporating any antigens, including without limitation allergens, for asthma, allergic rhinitis, COPD or for any other indication, whether the materials comprising such combinations are administered simultaneously or separately at different sites or times, and/or (iv) any and all drug combinations incorporating any medications, monoclonal antibodies, or other agents unless such medications, monoclonal antibodies or other agents are for the prophylactic and/or therapeutic treatment of asthma, allergic rhinitis or COPD, or such other agents are formulations with excipients, carriers, or delivery vehicles whether the materials comprising such combinations are administered simultaneously or separately at different sites or times.

IPSCIO Record ID: 212650

License Grant
The Licensor grants to Licensee a non-exclusive, royalty-bearing license, with the right to grant sublicenses, under the Patents to Exploit the Licensed Product in the Field in the Territory and to Manufacture or have Manufactured the Compound in connection with such Exploitation of the Licensed Product.  Field shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans.  Delivery Method for the Licensed Product shall mean intramuscular or subcutaneous delivery.
License Property
The Licensor is the owner or licensee of certain rights in proprietary technologies involving immunomodulatory oligonucleotides.

“Licensed Product” shall mean a prophylactic vaccine containing the Compound co-formulated with the Antigen for delivery by the Delivery Method. No Licensed Product(s) may be developed for the prevention, treatment or control of any cancer nor may any clinical trial be conducted with clinical endpoints of prevention, treatment or control of any cancer.

Patents Claiming Priority to Patent Application Serial No. 08/276,358

Field of Use
“Field” shall mean the use of the Licensed Product for the prevention of infection by Hepatitis B Virus in humans. The Field specifically excludes any product for the prevention of disease, indications or disorders other than Hepatitis B Virus in humans and any product for the treatment of any disease, indications or disorders.

IPSCIO Record ID: 249711

License Grant
Licensor grants a co-exclusive license, except non-exclusive license for HIV, in accordance with the terms stated herein.

Licensor grants to the United Kingdom Licensee and to any affiliates the following licenses, with the right to grant sublicenses, under Technology to develop, have developed, make, have made, use, have used, sell, offer for sale, have sold, keep and/or import in the Territory and in the Field all Products and/or Combinations, subject to the following
– For Prophylactic Immunization within the Field, Licensor grants a Co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
• HPV ANTIGENS
• HBV ANTIGENS
• INFLUENZA ANTIGENS
• Chlamydia ANTIGENS
• Mycobacterium ANTIGENS
• RSV ANTIGENS
• Malaria ANTIGENS

– For Prophylactic Immunization within the Field, Licensor grants a non-exclusive license for the following Licensed Antigens and no other Antigens
• HIV ANTIGENS

– For Therapeutic immunization within the Field Licensor grants a co-exclusive license for the following Licensed Antigens, including combinations thereof, and no other Antigens
• HPV ANTIGENS
• HBV ANTIGENS
• Chlamydia ANTIGENS
• Mycobacterium ANTIGENS

License Property
The Product shall mean any and all pharmaceutical compositions for the Prophylactic Immunization and/or Therapeutic Immunization against infectious diseases in humans comprising one or more of the Licensed Antigens in combination with Adjuvant as an ingredient or component in any formulation, configuration, combination and/or delivery system, to the extent Adjuvant induces, augments, fine-tunes or enhances the Antigen specific immune response of such Licensed Antigens contained within Product.

The patents relate to the use of Nucleic Acid.

Field of Use
The field shall mean the use of Adjuvant in combination with Licensed Antigens as part of a Product and/or Combination for Prophylactic Immunization and/or Therapeutic Immunization against infectious diseases in humans, expressly excluding the Specific Field.

Specific Field shall mean the use of Adjuvant as part of or in conjunction with a DNA Vaccine or other than in combination with a Licensed Antigen.

Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.